Recommended Serologic Workup for Suspected PBC and AIH
For suspected primary biliary cholangitis (PBC), test anti-mitochondrial antibodies (AMA) first, and if negative, proceed with anti-sp100 and anti-gp210 antibodies; for suspected autoimmune hepatitis (AIH), test antinuclear antibodies (ANA), smooth muscle antibodies (SMA), anti-LKM1, and anti-LC1, with PBC-specific antibodies added when cholestatic features are present. 1, 2
Primary Biliary Cholangitis Serologic Algorithm
First-Line Testing
- AMA (anti-mitochondrial antibodies): This is the primary diagnostic marker for PBC and should be tested first in all suspected cases 1
- AMA has high sensitivity and specificity for PBC diagnosis
- When AMA is positive along with cholestatic enzyme pattern, diagnosis is established without need for liver biopsy in most cases
AMA-Negative PBC Testing
If AMA is negative but clinical suspicion remains high:
- Anti-sp100: Sensitivity 22.7%, specificity 96.5% 1
- Anti-gp210: Sensitivity 19.7%, specificity 99.0% 1
Critical interpretation points:
- Anti-gp210 has higher specificity (99%) making it particularly useful as a confirmatory marker 1
- Anti-sp100 provides modest increase in diagnostic yield but with slightly higher false-positive rate 1
- These antibodies are confirmatory tests, not screening tests—use only after negative AMA in cholestatic patients 1
- At 1% disease prevalence, anti-sp100 identifies ~227 true positives per 100,000 tested but generates ~3,465 false positives 1
- Anti-gp210 identifies ~197 true positives per 100,000 tested with only ~990 false positives 1
Autoimmune Hepatitis Serologic Algorithm
Standard AIH Panel
Type 1 AIH markers:
- ANA (antinuclear antibodies)
- SMA (smooth muscle antibodies)
Type 2 AIH markers:
- Anti-LKM1 (liver kidney microsomal type-1)
- Anti-LC1 (liver cytosol type 1)
When Cholestatic Features Present
This is a critical clinical decision point: 2
In adults with AIH and biochemical cholestasis:
- Test PBC-specific autoantibodies (AMA, anti-sp100, anti-gp210) BEFORE any other test 2
- If PBC antibodies are negative, proceed to magnetic resonance cholangiography to evaluate for PSC 2
In children with AIH:
- Magnetic resonance cholangiography is recommended for ALL childhood AIH cases regardless of cholestatic enzyme levels 2
- This is because PSC can manifest with AIH features in children and may evolve over time
Important Clinical Caveats
Subtyping AIH
- Do not subclassify adult AIH patients based on autoantibody profiles—this is not clinically useful 2
- The historical AIH-1, AIH-2, AIH-3 classification system should not guide management decisions
Overlap Syndromes
- PBC-AIH variant requires liver biopsy for diagnosis 3
- Features can occur sequentially, so periodic re-evaluation of diagnosis is necessary 3
- The dominant disease should be named first (e.g., AIH/PSC or AIH/PBC when AIH predominates) 2
Timing Considerations
- In cholestatic presentations, testing for PBC antibodies takes priority over imaging to avoid unnecessary procedures 2
- Repeat cholangiography may be needed during follow-up if disease activity persists or cholestatic features develop 2
False-Positive Risk Management
The high false-positive rates with anti-sp100 and anti-gp210 are mitigated by:
- Testing only in highly selected patients already evaluated clinically, biochemically, and with imaging 1
- UDCA has favorable safety profile, so minimal harm if initiated in rare misclassified patients 1
- More concerning is the high false-negative rate (773-803 per 100,000 at 1% prevalence), which necessitates liver biopsy when antibodies are negative but suspicion remains high 1